Antidepressant consumption in the immigrant population registered at the health centres in this Health Region was between 40% and 75% lower than in the native population of the same age and sex (prevalence ratio of native vs. immigrants between 1.64 and 4.1).
Comparison with other countries
This finding corroborates the differences already reported in countries which traditionally have high rates of immigration. A recent systematic review by Uiters et al. underlined the importance of the effect of the host country and its health system on the use of services by the immigrant population. Those authors found more differences in countries with weaker primary care systems such as the US than in areas with stronger primary health care such as Canada and Europe [
14].
In the United States, various studies in broad samples coincide in demonstrating that access to AD is especially limited in Afroamericans [
15‐
17]. Williams et al. analysed data from national mental health surveys for Black Africans, White Americans and Black Caribbeans; although the lifetime prevalence of depression was lower in the Black population, the disorder was more persistent and severe, in spite of the fact that they received less AD treatment [
17].
In Europe the prevalence of mental illness has been examined in ethnic minorities, and although less research has been conducted of their pharmacological treatment some studies suggest the existence of differences. One study in the UK, for example, found that Asians received fewer AD and anxiolytics than the rest of the population [
18].
As we noted above, studies of mental illness in immigrants have been carried out in Spain, but few compare the rates of pharmacological treatment received by immigrants and natives. Most of those conducted to date are based on interviews of small samples, selected using different criteria which do not allow analysis of the differences between subgroups from different cultures.
In the analysis we included a variety of factors that may have a bearing on the lower use of AD in the immigrant group.
The first point to consider is whether the prevalence of depression is the same across the populations. It has been suggested that there are substantial differences across ethnic subgroups. Unfortunately, the data available from different countries in the world are difficult to compare due to the differences in the diagnostic criteria and instruments applied and in the demographic characteristics of the samples studied. In Spain, the most recent information, from the ESEMeD project (2009), reported a prevalence of major depressive episode above 4% in the last year or 10.6% during the lifetime, rates lower than those found in the other western countries that took part in the project [
19]. In Latin America, using similar criteria, yearly prevalence of 4.9% [
20] and lifetime prevalence of 9.2% [
21] has been reported. In Africa, studies with similar methodologies have also obtained variable yearly prevalence: Nigeria 1.1% [
22], Ethiopia 4.4% [
23], South Africa 4.9% [
24]. Studies in Eastern European countries using different instruments have obtained higher prevalence, ranging from 21% in Poland and 33% in Russia [
25]. Finally, there are few data from North African countries, but a study of the prevalence of anxiety and depression in immigrants living in the Netherlands found figures of 10% in Moroccans (and 19% in Turks) compared with 6.6% in the native Dutch population [
26]. With occasional exceptions, then, the prevalence of depression in immigrants from these areas is not lower than that found in the Spanish population and does not explain the large difference in treatment, although inter-ethnic differences should be taken into account.
Secondly, the lack of objective data on the prevalence of depression in our immigrant sample means that we cannot evaluate the hypothesis of undertreatment because of underdiagnosis. This hypothesis has been suggested by multiple studies: in the US, for example, Borowsky et al. found that primary care physicians were less likely to detect mental health problems among African Americans and Hispanics than among White Americans [
27]. Later studies obtained similar rates of prescription of AD treatment for the three groups, but reported a much lower likelihood that Africans and Hispanics would take the medication than Whites [
28]. Although the latter result suggests that GPs are now more alert to the problem and are better at diagnosing depression in countries where the subject has been researched for many years, it does not explain why the differences in AD consumption persist.
Treating patients from other cultures remains a significant problem for primary care physicians in most countries. The obstacles they face include the inadequacy of the diagnostic tools and clinical guides at their disposal and the difficulty of distinguishing between the symptoms caused by traumatic experiences and adverse life conditions and those caused by depression. They may also need to overcome gender stereotypes in mental illness to avoid under- or over-estimation of depressive symptoms [
29].
The third factor to consider is the low level of contact with health system [
30]. The lower the contact, the lower the levels of diagnosis and treatment. Indeed, in our study, the percentage of immigrants visiting the doctor at the health centres was lower than that of the native population (68.7% vs. 81.6%). These data corroborate the findings of previous studies (e.g. Saura et al., [
5]), and have been attributed to the lack of information regarding the health system and of the possibilities of access for those who are not legally resident [
3]. In our study, however, all the population included were legally entitled to health care, and had been registered with their health centre for at least one year; therefore, the obstacles would not be to do with the subjects' legal status but with other no less important causes such as linguistic difficulties, cultural differences in the perception of the need to seek medical advice, or the search for alternative solutions to health problems.
Another parameter to take into account in relation to depression is the time already spent in the country. The illness usually emerges as time passes and as immigrants begin to feel that their expectations have not been fulfilled [
31]. As we had no precise information on this issue we used an indirect indicator - the date of entry to the health system in the region - as a measure of time flows, of the stability of subjects' residence in the region, and of their adaptation to the local environment over time. Most of the immigrants had arrived in the last four years: the Maghribis and Latin Americans were the most stable groups, although the low numbers of individuals with more than five years' residence means that the results for longer periods should be interpreted with caution. In all age groups, AD consumption increased with time registered in the IPR, supporting the hypothetical model of the healthy immigrant whose health deteriorates with the passing of time. Furthermore, the groups with the highest rates of AD use, the Latin Americans and Eastern Europeans, were not the ones who had spent the longest in the region, a finding that suggests the influence of other factors related to the culture of origin.
Finally, we should stress that the decision to withdraw medication from the pharmacy is taken by the patient. A GP or psychiatrist may prescribe a drug, but the patient's intention to take it may be influenced by a range of circumstances. For instance, immigrant populations generally have low economic resources and the obligation of paying 40% of the price of the drug may be a deterrent. The acceptance of the diagnosis and the pharmacological treatment may also influence the decision to take the medication; in a study in the US, Cooper et al. observed a lower likelihood to accept AD medication in African Americans and Hispanics and a higher prevalence of negative beliefs [
32].
Differences across ethnic groups
The group with the highest AD consumption was the Latin American group, especially the women, and the one with the lowest was the sub-Saharan group, although the samples are too small to be able to generalize the results. Possibly these findings reflect the fact that the cultural and linguistic differences vis-à-vis the study setting are far greater in the case of the sub-Saharans than in the case of the Latin Americans.
In the case of the sub-Saharans, the concept of depression has changed radically in recent times. Historically non-existent or extremely rare, the prevalence of depression in these countries is now equal to or higher than those reported in the developed world, even among different ethnic groups. Recent studies of attitudes to mental illness in low-income communities in South Africa report stigmatization of mental patients, ignorance of the causes, and little effort to seek treatment [
33]. A broad survey carried out in 2007 in the US found that ethnic minorities were less likely to believe in the effectiveness of medication or in the biological basis of depression, and more likely to believe in the effectiveness of advice and prayer [
34]. Clearly, there is a need for further studies of attitudes to mental illness in these groups.
Strengths and limitations
One of the strong points of the present study is its large population-based sample and its comparison of the results of immigrants and the native population, with data from 232,717 Spanish nationals, 12077 Eastern Europeans, 8346 Maghribis, 6641 Latin Americans, 5412 sub-Saharans and 885 individuals of other nationalities. As the proportions according to area of origin and sex of the sample matched those published by the Catalan Statistics Institute for the same year, 2008 [
11], we believe that our data are representative of the populations of origin, even though the study was performed in a specific geographical area.
The main limitations of the study are due to the selection of the sample. First, immigrants who were not legally registered in Spain were not included, since they do not have an identity card or health or pharmaceutical coverage. For this reason, the results can only be extrapolated to immigrants who are legally registered. Second, to establish whether the immigrant population assigned to health centres was representative of the immigrants in the health region as a whole we compared their distribution with the data from the municipal census. We found that the Latin Americans, Maghribis and sub-Saharans registered at the health centres accounted for between 80% and 90% of those registered on the census, but in the case of the Eastern Europeans the figure fell to 70%. We cannot rule out the possibility of a selection bias, especially in the latter group, as we do not know whether the population that has not contacted the health system differs in terms of mental health from the population studied. Third, we also decided to exclude patients who registered for the first time, moved, or died during the calendar year studied in order to make sure that the observation period was the same for all subjects. Fourth, as regards the country of origin, our decision to classify as native all subjects who did not report their country of origin and who had been living in the study area at the end of 2002, when the proportion of immigrants was under 5%, may have introduced a bias. Equally, in grouping the patients into four areas of origin to increase the power of the analysis we used our own subjective criteria of ethnic/cultural similarity, which are obviously debatable.
We stress that AD prescription does not necessary imply the diagnosis of a depressive disorder, since these drugs may also be prescribed for other health problems [
35]; however, this limitation would be expected to affect all the population equally, regardless of their country of origin. Nor does the act of obtaining medication from the pharmacy guarantee compliance with treatment. Establishing the prevalence of depressive disorder in the two groups and assessing compliance with treatment are beyond the scope of this analysis, but there is no doubt that this information would be useful for evaluating the conclusions, and so attempts should be made to determine these variables in future studies.
We are also aware of the possibility of obtaining AD from other sources, but this appears difficult because, in Spain, AD can only be dispensed with a medical prescription and thus would be registered in the database. As far as we know, there are no other organizations in the HR that can provide this service.
Finally, the analysis of AD consumption was performed using an electronic database of prescriptions. Databases of this kind have demonstrated their usefulness for epidemiological analysis of medication consumption patterns in various clinical entities [
36‐
42] carried out from a population perspective.